๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zai Lab Limited (HKG:9688)
Hong Kong flag Hong Kong ยท Delayed Price ยท Currency is HKD
16.39
-0.96 (-5.53%)
Nov 20, 2026, 4:08 PM HKT
โ† View all transcripts

Study update

Nov 13, 2026

Summary

In 48 healthy volunteers, ZL-1503 showed a 40โ€“50-day half-life, no detected anti-drug antibodies, and โ‰ฅ90% pSTAT inhibition through week 12 at 200โ€“1,000 mg. Patient MAD and IV-to-subcutaneous bridging data are expected in H1 2027.

Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's 2026 ACAAI Investor Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Rafael Amado, President and Head of Research and Development of Zai Lab. Please go ahead, sir.

Rafael Amado
President and Head of Research and Development, Zai Lab

Good morning, everyone. Thank you for joining us today. My name is Rafael Amado, and I am President and Head of Research and Development for Zai Lab. Later this afternoon, at the American College of Allergy, Asthma & Immunology Annual Meeting, we will be presenting the first clinical data for ZL-1503, our internally discovered long-acting bispecific antibody that blocks both IL-13 cytokine ligand and IL-31 receptor alpha. We went into the phase I/I-B study with clear questions about safety, half-life, and target engagement. ZL-1503 met every objective that we tested in this healthy volunteer study. The study continues with further follow-up and multiple ascending doses in patients with atopic dermatitis. This MAD data will be available in the first half of next year. Our forward-looking statements are on slide two.

Moving to today's agenda, I will walk through the highlights of our presentation at the conference and what it means for the program, and then I will open up for questions and answers. Briefly, for context on our global R&D programs, ZL-1503 is our leading immunology program. Zoci, our DLL3 antibody-drug conjugate, is our lead oncology program, with registrational data in extrapulmonary neuroendocrine carcinomas and small cell lung cancer next year, setting us up for our first potential U.S. submission next year. Other global oncology programs are listed, including an additional ADC currently in phase I, a T-cell engager, and immunocytokine, both in IND-enabling studies for INDs in December of this year and the first quarter of next year, respectively. Today, though, the focus is entirely on ZL-1503. Therapies for atopic dermatitis are evaluated across key attributes, lesion control, itch relief, dosing convenience, and safety.

We designed the phase I/I-B program to test ZL-1503 across each one of these attributes. Here is what the healthy volunteer data set showed us. On IL-13 blockade, a single dose of ZL-1503 produced at least 90% inhibition of pSTAT, or phospho-STAT, through at least week 12 at 200, 600, and 1,000 mg in peripheral blood. We are seeing strong IL-13 pathway inhibition. Second, dosing. The mean terminal half-life was approximately 40 - 50 days, with dose-proportional exposure. This supports the potential for extended dosing in maintenance. Third, safety. There were no serious adverse events, no dose-limiting toxicities, and no anti-drug antibodies detected as of the data cutoff. The fourth question, itch, needs data from patients with atopic dermatitis, which we plan to present next year.

That said, we have already some compelling preclinical data demonstrating IL-31 receptor alpha blockade comparable to nemolizumab in vitro and sustained itch suppression for up to 112 days in non-human primates and a transgenic murine model. I want to explain why itch matters so much in atopic dermatitis and why we designed ZL-1503 to target it directly. Itch is among the most distressing symptoms for this disease. More than half of adults with atopic dermatitis name it as the most burdensome symptom. Nearly three-quarter of patients with more extensive disease report severe itch in the previous week, and more than 90% report moderate to severe sleep disturbance. Overall, severe atopic dermatitis has an enormous impact in health-related quality of life, comparable or worse in some domains to chronic conditions such as heart disease or diabetes, according to peer-reviewed journals. Itch also contributes to the disease.

Itching leads to scratching disrupts the skin barrier, allergens and irritants penetrate the skin, and inflammation can be perpetuated, preventing pruritus improvement. ZL-1503 targets two clinically validated pathways. IL-13 drives the inflammatory cascade through Th2 differentiation, eosinophil and mast cell activity, and IgE production. IL-31 signaling through IL-31 receptor alpha activates sensory nerves that drive itch. IL-4 receptor alpha blockade can increase IL-4 and can also alter Th2/Th1 balance, leading to a degree of autoimmune dysregulation. IL-4 tends to be lesional in the skin, while IL-13 is diffusely distributed. The biology is proven. The question is whether one molecule can hit both cleanly with less frequent dosing. We think ZL-1503 can. ZL-1503 is a full IgG antibody against IL-13 with a single domain VHH targeting IL-31 receptor alpha fused to the N-terminus of the light chain of anti-IL-13 antibody. The molecule is 171 kilodaltons.

The Fc region carries leucine replacement with alanine double mutations to reduce effector function, and YTE mutations to extend serum half-life, supporting the potential for longer dosing intervals. Preclinically, ZL-1503 strongly inhibited both IL-13 and IL-31 signaling and had a favorable safety profile. Turning to itch, because IL-31-driven itch can't be measured in healthy volunteers, I wanted to share our data with our preclinical models. We tested both arms in non-human primates. A single intravenous dose produced dose-dependent suppression of monkey IL-31-induced scratching. The left panel shows PK showing dose-dependent exposure, and on the right panel, we see at 10 mg per kilogram, one dose suppressed scratching through day 112, counted utilizing artificial intelligence. Duration of inhibition tracked exposure, so we saw a clear PK/PD relationship. This preclinical data gives us confidence that ZL-1503 can deliver meaningful itch relief.

We look forward to sharing the first data in patients with atopic dermatitis. Now for the clinical data. Turning to our clinical program, ZL-1503 is a global, randomized, double-blind, placebo-controlled phase I/I-B study. The study has two parts. Part A, the single ascending dose portion we're presenting today, enrolled 48 healthy volunteers across six cohorts, randomized 6:2 to ZL-1503 or placebo in each cohort at intravenous doses from 50 mg to 1,000 mg. The primary endpoint is safety, with PK and immunogenicity as secondary endpoints, and phospho-STAT, TARC, CCL26, and IgE as pharmacodynamic biomarkers. Part B is a multiple ascending dose study in patients with moderate to severe atopic dermatitis. Two cohorts are included of 12 and 24 patients in two intravenous ascending doses. Alongside safety, PK, and biomarkers, it measures efficacy, lesion control by EASI and IgA, itch, and sleep.

On the next slide, baseline characteristics were generally balanced across cohorts. The majority of participants were Caucasian or Asian. All healthy volunteers, cohorts 600 mg and 1,000 mg, include twice as many patients, as they were done as separate cohorts in China in addition to New Zealand. Moving to safety. ZL-1503 was well tolerated across all doses up to 1,000 mg. There were no serious adverse events, no dose-limiting toxicities, and no adverse events leading to treatment interruption. There was a single grade three TEAE in a placebo participant. Otherwise, toxicity mostly related to injection site complaints. There were no grade three or higher treatment-emergent events on ZL-1503 dose participants. Most frequently, adverse events were mild and related to study procedures such as bruising from blood draws. Next slide.

Exposure increased proportionally with dose from 50 to 1,000 mg, and the mean terminal half-life was approximately 40 - 50 days across all doses, about twice the published half-lives of approved IL-4, IL-13, and IL-31 receptor antibodies. PK was consistent with our Chinese and New Zealand cohorts at 600 and 1,000 mg. Importantly, no anti-drug antibodies were detected as of the data cutoff across all those ZL-1503 participants. In summary, first, the YTE half-life extension prolongs exposure in humans. Second, dose-proportional PK profile gives us a reliable basis for modeling regimens from 50 to 1,000 mg. And third, the absence of detectable anti-drug antibodies is encouraging as we move towards repeat dosing. Ultimately, our goal is to identify a regimen that can provide both lesion control and rapid and sustained itch relief with less frequent dosing. Next slide. We assessed IL-13 pathway inhibition with four biomarkers.

Phospho-STAT is the most direct. Inhibition of IL-13-stimulated STAT phosphorylation shows the pathway is blocked. TARC and CCL26 are downstream chemokines that reflect type 2 helper cell-mediated inflammation, and IgE is a broader marker of type 2 immune activity. These biomarkers help show whether ZL-1503 engages its target and suppresses the downstream signaling that drives disease. On phospho-STAT, a single dose of ZL-1503 produced rapid, near-complete inhibition of IL-13-stimulated phospho-STAT. Inhibition was evident in the first post-dose measurement at 200, 600, and 1,000 mg, and it was 90% or greater through week 12. Phospho-STAT was not measured between weeks 12 and 24. The 1,000 mg week 24 result wasn't available at the data cutoff. The duration of inhibition was dose-dependent, consistent with the PK that we just saw. The results show durable blockade of the IL-13 pathway, supporting the potential for extended dosing intervals.

ZL-1503 also reduced TARC, or thymus activation regulated chemokine, also known as CCL17. TARC is a downstream chemokine associated with atopic dermatitis severity, produced by skin cells, dendritic cells, and endothelial cells that attract T helper cells to inflamed skin during the acute phase of atopic dermatitis. Single doses reduce circulating TARC across dose levels comparable to what's been reported with dupilumab. TARC levels are low in these healthy volunteers, but in spite of that, we see meaningful TARC suppression. Beyond TARC, ZL-1503 reduced CCL26, an IL-13-inducible chemokine linked to eosinophil recruitment. Reductions of 20%- 30% appear within the first week across all active doses, while placebo remained flat, and they persisted through week 24. We also saw an early trend towards IgE at higher doses.

IgE declines slowly because of its long half-life, so longer follow-up and data in patients with atopic dermatitis will give us a clearer picture. In summary, pSTAT, TARC, and CCL26 show that ZL-1503 inhibits IL-13 signaling and its downstream effects, which transcends beyond the time of IC90 for pSTAT suppression in the case of CCL26 and IgE. What does this mean for patients? Today's patients face trade-offs. IL-13 and IL-4 receptor antibodies provide strong lesion control, but itch relief takes longer. Nemolizumab provides rapid itch relief with more modest lesion control. JAK inhibitors offer both, but carry a boxed warning. ZL-1503 is designed to remove those trade-offs. Lesion control is in line with the IL-13 class, rapid itch relief through IL-31 receptor alpha blockade. We believe that comprehensively interrupting the itch-scratch inflammation cycle has the potential to translate into best-in-class results for patients.

Furthermore, on dosing, patients on dupilumab inject 26 times a year. With lebrikizumab and nemolizumab, maintenance is between seven and 13. ZL-1503 has a half-life that is 2x at least the approved agents and pSTAT inhibition that holds for months. ZL-1503 has the potential for maintenance dosing every three months or more, equating to about four injections a year after induction treatment. That's a reduction of up to 80% versus every two-week dosing with meaningful control of inflammation, in line with dupilumab and lebrikizumab, and rapid and persistent control of pruritus commensurate with nemolizumab. We see Q3 months as the optimal dosing schedule. Beyond that, the added convenience matters less. However, the final interval will be set by repeat dose data in patients and tested in phase II-B with a subcutaneous formulation. Lastly, ZL-1503 has demonstrated good safety.

Taken together, we believe 1503 has a profile that can be highly differentiated in this market. Now, looking ahead, 2027 is an important year of catalysts. In the first half of 2027, we expect the first data in patients with atopic dermatitis from the multiple ascending placebo-controlled dose part of the phase I/I-B study, including PK, PD, lesion control, and itch. Our IV to subcutaneous bridging study is now fully enrolled, and we expect data in the first half of the year. Together, this data will guide dose and regimen selection for a global phase II-B study that we plan to initiate in 2027 using an already available subcutaneous formulation. We look forward to sharing updated data on this program throughout the year. With that, I'll open it up for questions.

Operator

Thank you. We will now begin the question-and-answer session. To ask a question now, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. A moment for our first question. Our first question comes from Li Watsek from Cantor. Please go ahead, Li. Your line is open.

Li Watsek
Analyst, Cantor

Hey, good morning. Congrats on the great data. Given the 40-day half-life with the IV formulation, how should we think about the translation or the rate to the sub-Q, and what is your confidence level for Q2 month or Q3 month dosing regimen?

Rafael Amado
President and Head of Research and Development, Zai Lab

Thank you for the question. As I said before, we have a very high-yield sub-Q formulation that is ready for the clinic, and we finished the bioequivalence study between IV and sub-Q. Those data are still to be analyzed, but we don't expect any changes in the subcutaneous formulation with regards to half-life. I think because of the high yield, it will allow us to test high doses. Like other products, it will probably consist on a regimen of short induction followed by Q3 monthly dosing. That's what we expect. Most of these products have either autoinjectors or prefilled syringes, and they end up injecting in two different sites to give the upper dose. We don't yet know whether we will be able to just inject once or twice, that's what the phase II-B study is for.

We will learn a lot, I think, from the IV, because we don't think there will be very many differences. We've already started to think about modeling, and of course, we need some assumptions with regards to absorption of the subcutaneous formulation to be able to do that. We want to be above concentrations of lebri and some of the existing products. But we're very confident that after a short period of induction, Q3 month should be viable.

Operator

Thank you. We will now go to our next question, and our next question comes from Daina Graybosch from Leerink Partners. Please go ahead, Daina, your line is open.

Daina Graybosch
Analyst, Leerink Partners

Hi. Congrats on the great data. I wonder if you could talk about the design, the format, and what in the format you think is leading to the two really promising aspects, both the long PK, so you're not getting a lot of receptor-mediated rapid clearance, and the lack of ADAs. Thank you.

Rafael Amado
President and Head of Research and Development, Zai Lab

Yeah, good question. I think there may be some TMDD initially, but it's mild. The other thing I would say is that in all the products that have been tested before, the PK in healthy volunteers and atopic dermatitis tends to be very similar. We do not expect dramatic changes in the PK in the MAD portion of the study. It just doesn't seem to be a very immunogenic product. I mean, there are a lot of examples of single injection leading to anti-drug antibodies. Not all of them are neutralizing, and some of the products that are under development are engendering ADAs, so far not affecting the PK, as far as I know. But we're not seeing that looking with a very sensitive bioluminescence assay, and we're looking at both idiotypes, 13 and 31.

I think it's because of the humanization, and also it's just a single VHH region for IL-31 blockade, receptor alpha, which is pretty small. So the molecule is fully humanized. We obviously need to wait for the repeat dosing, but so far, we haven't seen anything. We did see something in animals, but that is very common, and that never predict what will happen in humans. So, fingers crossed that the MAD data will show us the same type of clean results that we're seeing now.

Operator

Thank you. We will now move to our next question, and our next question comes from Michael Yee from UBS Securities. Please go ahead, Michael, your line is open.

Kyle Yang
Analyst, UBS Securities

Hey, guys. Thanks for taking our questions. This is Kyle Yang for Michael Yee. Just a quick one for us. Perhaps on the upcoming MAD data in atopic dermatitis patients, could you talk about the study design in terms of the size of the trial, the endpoints you are going to measure? Also, what is your expectation for the efficacy readout? Also, what is the timeframe of the study? Is it four-week or 12-week study? Thank you.

Rafael Amado
President and Head of Research and Development, Zai Lab

Yes, thanks for the question. The MAD will enroll 36 patients with moderate to severe atopic dermatitis. It is a randomized, double-blind placebo control, 3:1 of ZL-1503 to placebo in two different cohorts. Each cohort will study a different dose. We are honing into two different doses intravenously. The second cohort will have more patients than the first cohort. In terms of what we are looking at, it will be the list of endpoints that you just saw, safety being even more important because these are patients. Then we will look at vIGA-AD , the various EASI scores, including 75 and 90, which equates very similar to IgA. Importantly, we will look at pruritus with the PP-NRS score, and sleep disturbances, and other elements of quality of life, and elements of inflammation, such as the eczema measurement.

It will be sort of a full assessment of efficacy. The patients will be taken out to week 16. The treatment will be early on, and then we will measure effect out to week 16. In terms of the timing, we think we have already accrued to the first cohort, and we will get results on the two cohorts in the first half of next year and should be able to report during that time. I do not know if I missed any components of your question, but I hope that was comprehensive enough.

Kyle Yang
Analyst, UBS Securities

That was clear. In terms of doses, how many induction doses are there?

Rafael Amado
President and Head of Research and Development, Zai Lab

There's induction doses are three doses, and we don't treat long term. There will be some distinctions from some of the other competitors that you may have seen, where they've dosed at week 12, for instance, and they've dosed at higher doses. There is a dose response in this disease up to a point where the results become more asymptotic. We will dose more often, and even week 12 to week 16, and we will explore variabilities on dosing until we get to the maintenance setting, which we want to get very quickly in the phase II-B. Early on in this study, we're only given three doses and wait until week 16.

Kyle Yang
Analyst, UBS Securities

Super helpful. Thank you.

Operator

Thank you. Our next question comes from the line of Yigal Nochomovitz from Citigroup. Please go ahead, Yigal, your line is open.

Yigal Nochomovitz
Analyst, Citigroup

Hi. Thank you for taking the questions. I just had a few here on the PK/PD. With regard to the measurement of the IL-13 cytokine and IL-31, obviously, I know these are healthy volunteers, but nonetheless, were you able to measure free IL-13 in plasma, which obviously would go down, and then free IL-31, which I would think would maybe go up since you're blocking the receptor? That's one question. The other one is, it looks like from the PK/PD, over 200 mg it seems like pSTAT6 is kind of at the assay ceiling. Just wondering as far as how you would identify a minimal useful exposure, considering it looks like you're getting pretty good blockade at over 200. Thanks.

Rafael Amado
President and Head of Research and Development, Zai Lab

Yeah, very good questions. We did not look at IL-13, 31 in these healthy volunteers. Actually, I would imagine the levels are low, but it may be a retrograde loop on IL-31 going up. We definitely know that in IL-4, when it is blocked, IL-4 cytokine does go up. It is an interesting question, and I will bring it up to see whether we can do exploratory analysis to look at this. I think with pSTAT6, we were pretty pleased to see this long-term inhibition. It is not even clear that IC90 is the right level and whether it really correlates well with disease control. You can see that some of the pharmacodynamic endpoints actually lag after pSTAT inhibition, and that would make sense. We obviously aim to have that below the IC90 for as long as possible.

The only other thing I would say is that we did not measure, as I said in the prepared remarks, between 12 and 16 and 24, so we just extrapolated and carried it forward. It is possible that it may have remained suppressed out to a few more weeks before it went up by 20% at week 24. Hopefully this answered your questions, but we were very pleased that these relatively few doses were able to control IL-13 and pSTAT6 phosphorylation, which I think most people in the field believe that hitting that hard early on during induction is important.

Yigal Nochomovitz
Analyst, Citigroup

Just one quick follow-up. The 90% greater than hitting at pSTAT6 inhibition at week 12, was that every patient that got that, or is that the average?

Rafael Amado
President and Head of Research and Development, Zai Lab

Yeah, that is the average of pretty much every patient got it.

Yigal Nochomovitz
Analyst, Citigroup

Oh, all right. Got it. Thank you.

Operator

Thank you. As a reminder, before we move to our next question, please press star one one if you wish to ask a question. Our next question comes from the line of Anupam Rama from JPMorgan. Please go ahead, Anupam, your line is open.

Diogo Teles
Analyst, JPMorgan

Hi. This is Diogo Teles for Anupam Rama at JPMorgan. Thank you for taking our question. Based on today's healthy volunteer data, we have a couple of questions on itch in your atopic dermatitis patients. From a patient perspective, what is the importance of itch, and how do you see differentiation from competitors in the space?

Rafael Amado
President and Head of Research and Development, Zai Lab

Yeah, I love this question because eczema or atopic dermatitis is viewed as a skin condition, but it's more than a skin condition. The goal of many dermatologists is to get rid of pruritus because it is incredibly distressing to patients. They can cover the lesions, but they cannot stop scratching. When it is in children, the entire family suffers tremendous burden. There is not just the potential for superinfections in the lesion that happens with Staph aureus, exposure to allergens, and delays in healing the inflammation, but the patient is- And actually, the regulators have recognized this, have an impact in neurocognitive scales. So, a number of these scales need to be employed to be measured to develop these drugs, depression, suicidality, and other scales of how quality of life is manifested by pruritus.

It is a paramount symptom to control, which we look forward to see how it worked in the MAD. Eventually, when the inflammation goes away, pruritus subsides. But the important thing that we're trying to bring in with this dual inhibitor is immediate abrogation of pruritus on days one and two, at least a four-point drop in the PP-NRS scale, which is clinically significant. We're looking forward to seeing what the MAD data tells us about that.

Diogo Teles
Analyst, JPMorgan

Okay. Thank you so much.

Operator

Thank you. Once again, if you wish to ask a question, please press star one one on your telephone keypad. I'm showing no further questions. I'll now turn the conference back to Rafael for his closing comments.

Rafael Amado
President and Head of Research and Development, Zai Lab

Great. Thank you so much, all of you, for joining us this morning. I look forward to providing further updates next year, hopefully in the first half of the year. Operator, you may now disconnect.

Operator

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect your line.